Price movement over the last 24 hours
AdaptHealth Corp vs Koninklijke Philips NV — how do they compare? AdaptHealth Corp trades at $10.04 (market cap $1.38B), while Koninklijke Philips NV trades at $27.57 (market cap $27.30B). The key difference: Koninklijke Philips NV is far larger — about 19.8× AdaptHealth Corp's market cap, and Koninklijke Philips NV pays a 3.59% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | PHG | |
|---|---|---|
Market Cap | $1.38B | $27.30B |
Sector | Health | Health |
52-Week High | $13.38 | $32.91 |
52-Week Low | $8.68 | $24.03 |
Enterprise Value | $3.33B | $33.57B |
Dividend Yield | — | 3.59% |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
PHG trades at $28.23, up 1.77% with a bullish technical outlook supported by moving averages. The company shows improved profitability with net income turning positive at $895 million in 2025 after previous losses. Recent earnings beat expectations in two of the last three quarters, while analyst sentiment leans neutral with 40.9% buy ratings. Strong cash flow generation and strategic partnerships in healthcare technology position the company for continued recovery.
The stock presents a recovery story with improving fundamentals but faces execution risks in a competitive healthcare technology market. Valuation appears reasonable with P/E of 24.73 and P/S of 1.35, though debt levels remain elevated. Near-term catalysts include Q2 2026 earnings and continued AI integration in healthcare solutions, while macroeconomic pressures and competitive threats represent ongoing challenges.
Trailing returns across standard periods
Latest headlines on both assets
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →